These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15379778)

  • 1. Biologics in combination with nonbiologics: efficacy and safety.
    Stebbins WG; Lebwohl MG
    Dermatol Ther; 2004; 17(5):432-40. PubMed ID: 15379778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine: what clinicians need to know.
    Koo J; Lee J
    Dermatol Clin; 1995 Oct; 13(4):897-907. PubMed ID: 8785893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of infliximab in the treatment of psoriasis.
    Lee MR; Cooper AJ
    Australas J Dermatol; 2004 Aug; 45(3):193-5. PubMed ID: 15250904
    [No Abstract]   [Full Text] [Related]  

  • 4. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
    Naldi L; Griffiths CE
    Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of psoriasis. Part 2. Systemic therapies.
    Lebwohl M; Ali S
    J Am Acad Dermatol; 2001 Nov; 45(5):649-61; quiz 662-4. PubMed ID: 11606913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
    Aydin F; Canturk T; Senturk N; Turanli AY
    Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
    Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
    J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy to treat moderate to severe psoriasis.
    Lebwohl M; Menter A; Koo J; Feldman SR
    J Am Acad Dermatol; 2004 Mar; 50(3):416-30. PubMed ID: 14988684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinician's paradigm in the treatment of psoriasis.
    Lebwohl M
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S59-69. PubMed ID: 15968265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis.
    Zargari O
    Dermatol Online J; 2005 Dec; 11(3):21. PubMed ID: 16409917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate supplementation during methotrexate therapy for patients with psoriasis.
    Strober BE; Menon K
    J Am Acad Dermatol; 2005 Oct; 53(4):652-9. PubMed ID: 16198787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination immunosuppressive therapies: the promise and the peril.
    Robinson MR; Korman BD; Korman NJ
    Arch Dermatol; 2007 Aug; 143(8):1053-7. PubMed ID: 17709665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of ciclosporin in psoriasis: a clinical review.
    Ho VC
    Br J Dermatol; 2004 May; 150 Suppl 67():1-10. PubMed ID: 15115440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
    Yamauchi PS; Lowe NJ
    Int J Dermatol; 2008 Feb; 47(2):202-4. PubMed ID: 18211500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
    Yamauchi PS; Gindi V; Lowe NJ
    Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.
    Maryles S; Rozenblit M; Lebwohl M
    J Dermatolog Treat; 2003; 14 Suppl 2():7-16. PubMed ID: 14578093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
    Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
    Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.